summary: The authors looked at the effects of natalizumab, a recently introduced treatment for aggressive relapsing-remitting MS, on the levels of immature cells that eventually develop into blood cells. They found high levels of these cells circulating after the first dose of natalizumab, which were maintained during treatment. The clinical relevance of this is still unclear.

authors: Bonig H, Wundes A, Chang KH, Lucas S, Papayannopoulou T.

source: Blood. 2008 Apr 1;111(7):3439-41. Epub 2008 Jan 14.

weblink: click here

category: Immunology

related research news: click here

glossary: